Antibody platform Sanyou raises ~$15M Series C led by Zero2IPO

What's the deal? Sanyou BiopharmaceuticalsDealroom has a profile for this one. Try Dealroom → has raised nearly US$13.8M in a Series C round. Zero2IPO Industrial Investment Fund led the round, with 清科产投基金 also participating.

Why now? The round is the company's first priced financing in years. Sanyou previously closed a Series A in May 2020, a Series B in June 2021, and a B+ round in August 2022.

The signal: A near-US$13.8M round stands out in China's antibody-platform sector, where capital has kept flowing — Shanghai's 伊米诺康 announced a US$34.4M Series A in May 2026. After a long gap since its 2022 financing, Sanyou's return to the market signals renewed investor appetite for antibody-discovery platforms.

Read more: sohu.com

Image credit: Generated with Gemini